AbbVie ABBV Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxExpenseBenefit.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's deferred tax assets?
- AbbVie (ABBV) reported deferred tax assets of $137M in Q1 2026.
- How has AbbVie's deferred tax assets changed year-over-year?
- AbbVie's deferred tax assets decreased by 94.7% year-over-year, from $2.58B to $137M.
- What is the long-term trend for AbbVie's deferred tax assets?
- Over 5 years (2020 to 2025), AbbVie's deferred tax assets has grown at a -8.1% compound annual growth rate (CAGR), from $3.65B to $2.39B.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.